Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 60, Issue -, Pages 1-10Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2021.06.003
Keywords
Gestational diabetes; Fetal growth; Metformin; Maternal hyperglycemia; Insulin therapy
Categories
Funding
- European Commission
- FESR FSE 2014-2020
- Regione Calabria
Ask authors/readers for more resources
Maternal gestational diabetes mellitus can have adverse effects on the health of mothers and newborns, with studies showing the impact of maternal hyperglycemia on fetal growth and birth weight abnormalities. There is ongoing debate on the diagnosis and treatment of this condition, and future research should focus on addressing gaps in current knowledge.
Maternal gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy, which can adversely affect the short-and long-term health of mothers and newborns. In recent years, several studies have revealed the early impact of maternal hyperglycemia on fetal growth trajectory and birth weight abnormalities in GDM-exposed pregnancies. However, an intense debate continues regarding the mode and optimal timing of diagnosis and treatment of this condition. The purpose of this review is to provide a brief overview of the understanding of GDM and its implications for fetal growth, addressing the modulatory role of medical nutrition therapy and available pharmacological antidiabetic agents (i.e. insulin, metformin, and glyburide), and to identify gaps in current knowledge toward which future research should be directed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available